StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd > 2 new posts on LinkedIn in the last 24 hours

<< Previous

Bullboard Posts

Next >>

Comment by LithLoveron Nov 18, 2022 6:16pm

105 Views

Post# 35111880

RE:RE:RE:2 new posts on LinkedIn in the last 24 hours

https://www.linkedin.com/company/stagezero-lifesciences/

No alternative text description for this image

LithLover wrote: You can find the posts via the LinkedIn icon at the bottom of the stagezero website.

gojotv! wrote:
I don't see the LinkedIn posts, Lithlover.
Where are they?

LithLover wrote:

A study by researchers from Brigham and Women’s Hospital reveals that the incidence of early onset cancers — including breast, colon, esophagus, kidney, liver, and pancreas — has dramatically increased around the world, with the rise beginning around 1990.

“We found that this risk is increasing with each generation,” Shuji Ogino, professor, physician-scientist

https://ow.ly/36B150LH04b.

https://news.harvard.edu/gazette/story/2022/09/researchers-report-dramatic-rise-in-early-onset-cancers/#:~:text=A%20study%20by%20researchers%20from,the%20rise%20beginning%20around%201990

-----------------------------------------------------------------------------------------------

One of the most alarming cancer statistics is the percentage of cancers still being diagnosed in the later stages, despite the efforts of national cancer screening programs. Why are we still reaching people late? Here are a few key reasons:

- Postponement of cancer screening (especially during COVID)
- Most symptoms don't appear until the cancer has progressed
- Shortcomings in existing screening programs (i.e. inconvenience, access, missed cancers)

When cancer is found in the early stages, survival rates dramatically improve. With the emergence of liquid biopsies like ARISTOTLE® that can help detect multiple cancers from a simple blood draw, we can help find more cancers in the early stages.

Learn more at https://lnkd.in/eg4tgdrU

#earlymeanseverything #earlycancerdetection #findcancerearly #liquidbiopsy